{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:46:20Z","timestamp":1767869180555,"version":"3.49.0"},"reference-count":57,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) have revolutionized the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD), providing cardiorenal and metabolic benefits that extend beyond glycemic control. While their clinical efficacy is well established, the underlying molecular mechanisms remain only partially understood. This review focuses on current knowledge of SGLT2 expression and regulation in health and metabolic diseases, as well as transcriptional and epigenetic consequences of pharmacological SGLT2 inhibition. Human and experimental studies demonstrate that SGLT2 expression is confined to proximal tubular cells and regulated by insulin, the renin\u2013angiotensin\u2013aldosterone system, the sympathetic nervous system, oxidative stress, and transcriptional and epigenetic pathways. SGLT2 expression follows a biphasic pattern in metabolic disorder-associated CKD: upregulation in early phases and reduction in advanced stages. Evidence from animal models and single-cell transcriptomic studies indicates that SGLT2is normalize metabolic and inflammatory gene networks. To our knowledge, a recent single-cell RNA sequencing study provides the only currently available human dataset linking SGLT2i therapy with tubular metabolic rewiring and suppression of the energy-sensitive mechanistic target of rapamycin complex 1. Collectively, these findings support a model in which SGLT2 inhibition mitigates metabolic stress by restoring energy homeostasis across multiple nephron segments.<\/jats:p>","DOI":"10.3390\/ijms27020589","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:09:36Z","timestamp":1767712176000},"page":"589","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic\u2013Epigenetic Effects of Its Pharmacological Inhibition"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3625-852X","authenticated-orcid":false,"given":"Chiara","family":"Salv\u00e0","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2524-5218","authenticated-orcid":false,"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-2573","authenticated-orcid":false,"given":"Matteo","family":"Landolfo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria"},{"name":"Clinical and Molecular Sciences Department, University Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 Inhibitors and Cardiorenal Outcomes in Patients with or without Type 2 Diabetes: A Meta-Analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108861","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular Therapeutic Targets of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors beyond Heart Failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Neuen, B.L., Fletcher, R.A., Anker, S.D., Bhatt, D.L., Butler, J., Cherney, D.Z.I., Docherty, K.F., Inzucchi, S.E., Jardine, M.J., and Mahaffey, K.W. (2025). SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria. JAMA, online ahead of print.","DOI":"10.1001\/jama.2025.20834"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Staplin, N., Roddick, A.J., Neuen, B.L., Anker, S.D., Bhatt, D.L., Butler, J., Cherney, D.Z., Docherty, K.F., Fletcher, R.A., and Inzucchi, S.E. (2025). Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria. JAMA, online ahead of print.","DOI":"10.1001\/jama.2025.20835"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ferreira, J.P., Marques, P., Anker, S.D., Butler, J., Filippatos, G., Sharma, A., Vasques-N\u00f3voa, F., Mendon\u00e7a, L., Neves, J.S., and Packer, M. (2025). Effects of SGLT2 Inhibitors across the Spectrum of Albuminuria in Cardiovascular\u2013Kidney\u2013Metabolic Conditions: A Pooled Analysis of Randomised Trials. Diabetes Obes. Metab., online ahead of print.","DOI":"10.1111\/dom.70289"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pucci, C., Marazza, D.S., Preka, E., Mastrangelo, A., Montini, G., and Boyer, O. (2025). SGLT2 Inhibitors for Kidney Protection in Children: Expanding Horizons beyond Endocrinology. Pediatr. Nephrol., online ahead of print.","DOI":"10.1007\/s00467-025-06838-7"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors: Peculiar \u201cHybrid\u201d Diuretics That Protect from Target Organ Damage and Cardiovascular Events","volume":"30","author":"Sarzani","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","article-title":"Empagliflozin Protects Mice against Diet-Induced Obesity, Insulin Resistance and Hepatic Steatosis","volume":"66","author":"Radlinger","year":"2023","journal-title":"Diabetologia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","article-title":"Cardiometabolic and Renal Benefits of Sodium\u2013Glucose Cotransporter 2 Inhibitors","volume":"21","author":"Lee","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","article-title":"How Can Inhibition of Glucose and Sodium Transport in the Early Proximal Tubule Protect the Cardiorenal System?","volume":"39","author":"Vallon","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wu, Q., Zhang, J., Zhang, F., and Li, D. (2025). SGLT2 Inhibitors as Metabolic Modulators: Beyond Glycemic Control in Type 2 Diabetes. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1601633"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mao, Z.-H., Gao, Z.-X., Liu, Y., Liu, D.-W., Liu, Z.-S., and Wu, P. (2023). Single-Cell Transcriptomics: A New Tool for Studying Diabetic Kidney Disease. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.1053850"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of Human Sodium Glucose Transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"sfad265","DOI":"10.1093\/ckj\/sfad265","article-title":"Genetic and Clinical Characterization of Familial Renal Glucosuria","volume":"17","author":"Xu","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41467-021-22368-w","article-title":"Single Cell Transcriptional and Chromatin Accessibility Profiling Redefine Cellular Heterogeneity in the Adult Human Kidney","volume":"12","author":"Muto","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of Renal Glucose Handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00424-020-02361-w","article-title":"Glucose Transporters in the Kidney in Health and Disease","volume":"472","author":"Vallon","year":"2020","journal-title":"Pflug. Arch."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wicik, Z., Nowak, A., Jarosz-Popek, J., Wolska, M., Eyileten, C., Siller-Matula, J.M., von Lewinski, D., Sourij, H., Filipiak, K.J., and Postu\u0142a, M. (2022). Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.901340"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"131419","DOI":"10.1016\/j.ijcard.2023.131419","article-title":"The Interaction between Non-Coding RNAs and SGLT2: A Review","volume":"398","author":"Eyileten","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.118.111807","article-title":"Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells","volume":"94","author":"Takesue","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.kint.2025.01.044","article-title":"Metabolic Dysfunction\u2013Associated Kidney Disease: Pathogenesis and Clinical Manifestations","volume":"108","author":"Bansal","year":"2025","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"sfae195","DOI":"10.1093\/ckj\/sfae195","article-title":"Proximal Tubule Hypertrophy and Hyperfunction: A Novel Pathophysiological Feature in Disease States","volume":"17","author":"Kanbay","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70042","DOI":"10.1111\/dme.70042","article-title":"Obesity-related Glomerulopathy: How It Happens and Future Perspectives","volume":"42","author":"Tan","year":"2025","journal-title":"Diabet. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13098-015-0044-1","article-title":"Insulin Stimulates SGLT2-Mediated Tubular Glucose Absorption via Oxidative Stress Generation","volume":"7","author":"Nakamura","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BCJ20253103","article-title":"Multifaceted Roles of Epac Signaling in Renal Functions","volume":"482","author":"Pochynyuk","year":"2025","journal-title":"Biochem. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00232-010-9334-6","article-title":"Glucose-Induced Regulation of NHEs Activity and SGLTs Expression Involves the PKA Signaling Pathway","volume":"239","author":"Machado","year":"2011","journal-title":"J. Membr. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4093\/dmj.2023.0397","article-title":"Kidney Gastrin\/CCKBR Attenuates Type 2 Diabetes Mellitus by Inhibiting SGLT2-Mediated Glucose Reabsorption through Erk\/NF-\u039aB Signaling Pathway","volume":"49","author":"Zhang","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13105-012-0153-3","article-title":"Autocrine Modulation of Glucose Transporter SGLT2 by IL-6 and TNF-\u03b1 in LLC-PK1 Cells","volume":"68","author":"Galicia","year":"2012","journal-title":"J. Physiol. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1042\/CS20210094","article-title":"Angiotensin II Up-Regulates Sodium-Glucose Co-Transporter 2 Expression and SGLT2 Inhibitor Attenuates Ang II-Induced Hypertensive Renal Injury in Mice","volume":"135","author":"Miyata","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the Sympathetic Nervous System in Regulation of the Sodium Glucose Cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor\u2013Induced Sympathoinhibition","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109027","DOI":"10.1016\/j.diabres.2021.109027","article-title":"Renal Lipid Accumulation Induced by High-Fat Diet Regulates Glucose Homeostasis via Sodium-Glucose Cotransporter 2","volume":"179","author":"Chen","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cmet.2016.02.019","article-title":"Sodium Intake Regulates Glucose Homeostasis through the PPAR\u03b4\/Adiponectin-Mediated SGLT2 Pathway","volume":"23","author":"Zhao","year":"2016","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e21912","DOI":"10.1096\/fj.202100667RR","article-title":"High Salt Diet-induced Proximal Tubular Phenotypic Changes and Sodium-glucose Cotransporter-2 Expression Are Coordinated by Cold Shock Y-box Binding Protein-1","volume":"35","author":"Bernhardt","year":"2021","journal-title":"FASEB J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/s41440-023-01301-2","article-title":"Associations of SGLT2 Genetic Polymorphisms with Salt Sensitivity, Blood Pressure Changes and Hypertension Incidence in Chinese Adults","volume":"46","author":"Jia","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e164486","DOI":"10.1172\/JCI164486","article-title":"SGLT2 Inhibitors Mitigate Kidney Tubular Metabolic and MTORC1 Perturbations in Youth-Onset Type 2 Diabetes","volume":"133","author":"Schaub","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"F1224","DOI":"10.1152\/ajprenal.00370.2019","article-title":"Nephrotic Syndrome Study Network (NEPTUNE) Renal SGLT MRNA Expression in Human Health and Disease: A Study in Two Cohorts","volume":"317","author":"Ambinathan","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"zqae026","DOI":"10.1093\/function\/zqae026","article-title":"Megalin Knockout Reduces SGLT2 Expression and Sensitizes to Western Diet-Induced Kidney Injury","volume":"5","author":"Youm","year":"2024","journal-title":"Function"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Korsten, P., and Tampe, B. (2023). A Transcriptome Array-Based Approach to Link SGLT-2 and Intrarenal Complement C5 Synthesis in Diabetic Nephropathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242317066"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.hlc.2025.07.005","article-title":"Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond","volume":"34","author":"Allahwala","year":"2025","journal-title":"Heart Lung Circ."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11010-020-03686-x","article-title":"Inhibition of Tumor Necrosis Factor-\u03b1 Enhanced the Antifibrotic Effect of Empagliflozin in an Animal Model with Renal Insulin Resistance","volume":"466","author":"Mohamed","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Camacho, F., Zambrano-V\u00e1squez, O.R., Ar\u00e9chaga-Ocampo, E., Casta\u00f1eda-S\u00e1nchez, J.I., Gonzaga-S\u00e1nchez, J.G., S\u00e1nchez-Gloria, J.L., S\u00e1nchez-Lozada, L.G., and Osorio-Alonso, H. (2024). Sodium\u2013Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome. Antioxidants, 13.","DOI":"10.3390\/antiox13070768"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Koch, B., Fuhrmann, D.C., Schubert, R., Geiger, H., Speer, T., and Baer, P.C. (2023). Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24031811"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"115289","DOI":"10.1016\/j.biopha.2023.115289","article-title":"RNA-Seq Transcriptomic Landscape Profiling of Spontaneously Hypertensive Rats Treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","volume":"166","author":"Tan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ymthe.2021.10.013","article-title":"Kidney Single-Cell Transcriptome Profile Reveals Distinct Response of Proximal Tubule Cells to SGLT2i and ARB Treatment in Diabetic Mice","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cmet.2022.05.010","article-title":"Mapping the Single-Cell Transcriptomic Response of Murine Diabetic Kidney Disease to Therapies","volume":"34","author":"Wu","year":"2022","journal-title":"Cell Metab."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wolf, L., F\u00f6ller, M., and Feger, M. (2023). The Impact of SGLT2 Inhibitors on AKlotho in Renal MDCK and HK-2 Cells. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1069715"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e188933","DOI":"10.1172\/JCI188933","article-title":"SGLT2 Inhibition Protects Kidney Function by SAM-Dependent Epigenetic Repression of Inflammatory Genes under Metabolic Stress","volume":"135","author":"Maekawa","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101690","DOI":"10.1016\/j.xcrm.2024.101690","article-title":"The SGLT2 Inhibitor Dapagliflozin Ameliorates Renal Fibrosis in Hyperuricemic Nephropathy","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1186\/s12967-025-06788-6","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Alleviate Renal Fibrosis in Diabetic Kidney Disease by Inhibiting Hmgcs2 and Btg2 in Proximal Tubular Cells","volume":"23","author":"Yan","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e10615","DOI":"10.1016\/j.heliyon.2022.e10615","article-title":"Proximal Tubular Epithelia-Specific Transcriptomics of Diabetic Mice Treated with Dapagliflozin","volume":"8","author":"Nakamura","year":"2022","journal-title":"Heliyon"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/589\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:25:29Z","timestamp":1767849929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27020589"],"URL":"https:\/\/doi.org\/10.3390\/ijms27020589","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}